甘李药业与巴西本土企业签订超30亿元供应框架协议

Group 1 - The core viewpoint of the news is that Ganli Pharmaceutical has signed a technology transfer and supply agreement with Brazil's Ministry of Health's public laboratory Funda o Oswaldo Cruz-Bio-Manguinhos (FZ) and Brazilian biopharmaceutical company BIOMM S.A., with a contract amount expected to be no less than RMB 30 billion over a 10-year period [1][2][3] Group 2 - The collaboration is part of Brazil's Production Development Partnership (PDP) program, aimed at promoting local drug production through technology transfer from multinational pharmaceutical companies, ensuring a stable supply of essential medicines in Brazil [2] - Ganli Pharmaceutical is the first Chinese pharmaceutical company to enter the PDP program in Brazil, marking a new phase in Sino-Brazilian biopharmaceutical cooperation [2][3] - The approved proposal involves Ganli Pharmaceutical transferring technology related to insulin to FZ and supplying raw materials and injectable insulin to BIOMM, which will then transfer filling processes to FZ [3] - The agreement is expected to significantly enhance the stability of insulin supply in Brazil's public healthcare system over the next decade, addressing long-term medication accessibility issues for diabetes patients [3] - The independent commercial cooperation agreement with BIOMM covers raw materials, injectable insulin, and insulin pens, with a projected cumulative order amount of no less than RMB 30 billion over ten years [3] - Successful implementation of this agreement is anticipated to positively impact Ganli Pharmaceutical's operating performance in 2025 and beyond, enhancing overall profitability [3]